Incidence of Late-Stage Age-Related Macular Degeneration in American Whites: Systematic Review and Meta-analysis.

PURPOSE To estimate incidence of age-related macular degeneration (AMD) by subtype in American whites aged ≥50 years. DESIGN Systematic review and meta-analysis. METHODS SETTING Prospective cohort studies of AMD incidence in populations of white European ancestry published in MEDLINE, EMBASE, and Web of Science. STUDY POPULATION Fourteen publications in 10 populations that examined AMD incident cases were identified. OBSERVATION PROCEDURE Data on age-sex-specific incidence of late AMD, geographic atrophy (GA) and neovascular AMD (NVAMD), year of recruitment, AMD grading method, and continent were extracted. MAIN OUTCOME MEASURE(S) Annual incidence of late AMD, GA, and NVAMD by age-sex in American whites aged ≥50 years from a Bayesian meta-analysis of incidence studies was compared with incidence extrapolated from published prevalence estimates. RESULTS Incidence rates from the review agreed with those derived from prevalence, but the latter were based on more data, especially at older ages and by AMD subtypes. Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000. Late AMD incidence was 38% higher in women vs men (95% credible interval 6%, 82%). CONCLUSIONS Estimating AMD incidence from prevalence allows better characterization at older ages and by AMD subtype where longitudinal data from incidence studies are limited.

[1]  R. Klein,et al.  Prevalence of age-related macular degeneration in the US population. , 2011, Archives of ophthalmology.

[2]  P T de Jong,et al.  An international classification and grading system for age-related maculopathy and age-related macular degeneration , 1995 .

[3]  T. Peto,et al.  5-year incidence of age-related maculopathy in the Reykjavik Eye Study. , 2003, Ophthalmology.

[4]  C. Delcourt,et al.  The three-year incidence of age-related macular degeneration: the "Pathologies Oculaires Liées à l'Age" (POLA) prospective study. , 2005, American journal of ophthalmology.

[5]  Paul Mitchell,et al.  Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. , 2002, Ophthalmology.

[6]  Liang Xu,et al.  Mortality and ocular diseases: the Beijing Eye Study. , 2009, Ophthalmology.

[7]  G. Jensen,et al.  14-year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study. , 2005, Ophthalmology.

[8]  P. Mitchell,et al.  Smoking and age-related macular degeneration: a review of association , 2005, Eye.

[9]  A. Hofman,et al.  REVIEW: Epidemiology of age-related maculopathy: a review , 2003, European Journal of Epidemiology.

[10]  James Waterman Glover United States Life Tables , 2013 .

[11]  Ronald Klein,et al.  Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. , 2007, Ophthalmology.

[12]  S. Cummings,et al.  The association of smoking and alcohol use with age-related macular degeneration in the oldest old: the Study of Osteoporotic Fractures. , 2010, American journal of ophthalmology.

[13]  R. Klein,et al.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. , 1997, Ophthalmology.

[14]  E. Arias,et al.  United States life tables, 2006. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[15]  A. Hofman,et al.  The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. , 2003, Archives of ophthalmology.

[16]  Frank Eperjesi,et al.  Risk Factors for Age-related Macular Degeneration , 2011 .

[17]  R. Klein,et al.  The Wisconsin age-related maculopathy grading system. , 1991, Ophthalmology.

[18]  D. Moore,et al.  Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. , 2003, Health technology assessment.

[19]  P. Jong Prevalence of age-related macular degeneration in the United States. , 2004 .

[20]  P. Mitchell,et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis , 2010, BMC ophthalmology.

[21]  D. Cook,et al.  Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. , 2006, Investigative ophthalmology & visual science.

[22]  Paul Mitchell,et al.  Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. , 2007, Ophthalmology.

[23]  Benita J. O’Colmain,et al.  Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.

[24]  B. Munoz,et al.  Racial differences and other risk factors for incidence and progression of age-related macular degeneration: Salisbury Eye Evaluation (SEE) Project. , 2008, Investigative ophthalmology & visual science.

[25]  J M Gibson,et al.  Seven year follow-up of age-related maculopathy in an elderly British population , 1997, Eye.

[26]  A Hofman,et al.  Incidence and progression rates of age-related maculopathy: the Rotterdam Study. , 2001, Investigative ophthalmology & visual science.

[27]  A E Fletcher,et al.  How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? , 2003, The British journal of ophthalmology.

[28]  T. Wong,et al.  Age-related macular degeneration: why should stroke physicians care? , 2010, Stroke.

[29]  Richard Wormald,et al.  Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. , 2012, Ophthalmology.

[30]  Albert Hofman,et al.  Epidemiology of age-related maculopathy: a review. , 2003, European journal of epidemiology.

[31]  M G Maguire,et al.  Five-year incidence and disappearance of drusen and retinal pigment epithelial abnormalities. Waterman study. , 1995, Archives of ophthalmology.

[32]  M. C. Leske,et al.  Incidence estimates for lens changes, macular changes, open-angle glaucoma and diabetic retinopathy. , 1983, American journal of epidemiology.

[33]  R. Bronow Physicians who care. , 1987, Journal of the American Academy of Dermatology.

[34]  B. Stegmayr,et al.  Sex Differences in Stroke Epidemiology: A Systematic Review , 2009, Stroke.

[35]  H. Taylor,et al.  Five-year incidence of age-related maculopathy: the Visual Impairment Project. , 2004, Ophthalmology.

[36]  L. Smeeth,et al.  Cause-specific visual impairment and mortality: results from a population-based study of older people in the United Kingdom. , 2005, Archives of ophthalmology.

[37]  R. Klein,et al.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. , 2002, Ophthalmology.

[38]  Paul Mitchell,et al.  Clinical update: new treatments for age-related macular degeneration , 2007, The Lancet.

[39]  Paul Mitchell,et al.  Visual impairment, age-related macular degeneration, cataract, and long-term mortality: the Blue Mountains Eye Study. , 2007, Archives of ophthalmology.

[40]  P. Mitchell,et al.  The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. , 2010, Ophthalmology.